Compare Amphastar Pharmaceuticals Inc (AMPH) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Raytheon Technologies Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Raytheon Technologies Corp trades at $223.51 (market cap $302.06B). The key difference: Raytheon Technologies Corp is far larger — about 349.6× Amphastar Pharmaceuticals Inc's market cap, and Raytheon Technologies Corp pays a 1.3% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | RTX | |
|---|---|---|
Market Cap | $863.95M | $302.06B |
Sector | Health | Industrials |
52-Week High | $30.81 | $224.12 |
52-Week Low | $16.87 | $151.75 |
Enterprise Value | $1.26B | $332.61B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
RTX trades at $223.03, down 0.1% on the day, with a bullish technical outlook supported by moving averages and a recent $515 million Navy radar contract. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $88.6 billion in 2025, and net income margin improved to 8.28%. The stock is near its consensus price target of $233.14, with no analyst sell ratings.
The outlook for RTX is positive, driven by defense contract wins and expanding profit margins, but risks include high valuation multiples and geopolitical uncertainties. Earnings growth and execution on backlog are key catalysts for further upside, though the stock's elevated P/E ratio of 39.27 warrants caution amid potential market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
